Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 10Terminated 2Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 4Lymphoid 2Dermatologic 2Breast 2Sarcoma 1Other hematologic neoplasm 1Head & Neck 1Endocrine 1CNS 1

Conditions

Melanoma 2

Interventions

pembrolizumab 58Ipilimumab 53Cyclophosphamide 53Nivolumab 45aldesleukin 35Interleukin-2 26fludarabine phosphate 22fludarabine 21Vemurafenib 20Temozolomide 19Radiotherapy 19dabrafenib 15trametinib 12Radiosurgery 11CTLA-4 Antigen 11spartalizumab 10Filgrastim 10Dacarbazine 10cobimetinib 9binimetinib 9atezolizumab 9Biopsy 9poly ICLC 8Paclitaxel 8Antilymphocyte Serum 8encorafenib 7avelumab 7Rituximab 7Introns 7romidepsin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × AZD 6244 × Dermatologic × Clear all
NCT01519427 2014-06-18

Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib

National Cancer Institute (NCI)

Phase 2 Terminated
2 enrolled 9 charts
Dermatologic

Melanoma

NCT01166126 2014-05-15

Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV

National Cancer Institute (NCI)

Phase 2 Terminated
4 enrolled 7 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡